Vlahou A, Hallinan D, Apweiler R, Argiles A, Beige J, Benigni A, Bischoff R, Black PC, Boehm F, Céraline J, Chrousos GP, Delles C, Evenepoel P, Fridolin I, Glorieux G, van Gool AJ, Heidegger I, Ioannidis JPA, Jankowski J, Jankowski V, Jeronimo C, Kamat AM, Masereeuw R, Mayer G, Mischak H, Ortiz A, Remuzzi G, Rossing P, Schanstra JP, Schmitz-Dräger BJ, Spasovski G, Staessen JA, Stamatialis D, Stenvinkel P, Wanner C, Williams SB, Zannad F, Zoccali C, Vanholder R

Hypertension. 2021 Feb 15;:HYPERTENSIONAHA12016340

La Société de Biologie de Strasbourg : 100 ans au service de la science et de la société

Antony P, Fournel S, Zoll J, Mantz JM, Befort K, Massotte D, Giégé P, Céraline J, Metzger D, Becker H, Drouard L, Florentz C, Martin R, Nébigil C, Potier S, Schaefer A, Schaeffer E, Schuster C, Bresson A, Quéméneur E, Choulier L, Matt N, Monassier L, Lugnier C, Freysz L, Hoffmann J, Dreyfus H, Romier C

Biol Aujourdhui. 2020 ;214(3-4):137-148

ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder.

Carapito R, Ivanova EL, Morlon A, Meng L, Molitor A, Erdmann E, Kieffer B, Pichot A, Naegely L, Kolmer A, Paul N, Hanauer A, Tran Mau-Them F, Jean-Marçais N, Hiatt SM, Cooper GM, Tvrdik T, Muir AM, Dimartino C, Chopra M, Amiel J, Gordon CT, Dutreux F, Garde A, Thauvin-Robinet C, Wang X, Leduc MS, Phillips M, Crawford HP, Kukolich MK, Hunt D, Harrison V, Kharbanda M, ,,Smigiel R, Gold N, Hung CY, Viskochil DH, Dugan SL, Bayrak-Toydemir P, Joly-Helas G, Guerrot AM, Schluth-Bolard C, Rio M, Wentzensen IM, McWalter K, Schnur RE, Lewis AM, Lalani SR, Mensah-Bonsu N, Céraline J, Sun Z, Ploski R, Bacino CA, Mefford HC, Faivre L, Bodamer O, Chelly J, Isidor B, Bahram S

Am. J. Hum. Genet.. 2018 Dec 26;:

Dual effects of constitutively active androgen receptor and full-length androgen receptor for N-cadherin regulation in prostate cancer.

Cottard F, Madi-Berthélémy PO, Erdmann E, Schaff-Wendling F, Keime C, Ye T, Kurtz JE, Céraline J

Oncotarget. 2017 Sep 22;8(42):72008-72020

Dual effects of constitutively active androgen receptor and full-length androgen receptor for N-cadherin regulation in prostate cancer.

Cottard F, Ould Madi-Berthélémy P, Erdmann E, Schaff-Wendling F, Keime C, Ye T, Kurtz JE, Céraline J

Oncotarget. 2017 May;:

Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.

Destouches D, Sader M, Terry S, Marchand C, Maillé P, Soyeux P, Carpentier G, Semprez F, Céraline J, Allory Y, Courty J, De La Taille A, Vacherot F

Oncotarget. 2016 Oct;7(43):69397-69411

[Academic carriers in oncology and radiotherapy: Explanations for the readers of Bulletin du Cancer].

Soria JC, Bastian G, Bolotine L, Calais G, Céraline J, de Cremoux P, Espié M, Karayan-Tapon L, Laprie A, Mazeron JJ, Négrier S, Roché H

Bull Cancer. 2016 Sep;103(9):719-29

Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.

Hagberg Thulin M, Nilsson ME, Thulin P, Ceraline J, Ohlsson C, Damber JE, Welen K

Mol Cell Endocrinol. 2015 Nov 13. pii: S0303-7207(15)30138-6

Reversible amyloid fiber formation in the N terminus of androgen receptor.

Asencio-Hernández J, Ruhlmann C, McEwen A, Eberling P, Nominé Y, Céraline J, Starck JP, Delsuc MA

Chembiochem. 2014 Nov;15(16):2370-3

Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.

Terry S, Maille P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, Ceraline J, Firlej V, Beltran H, Allory Y, de la Taille A, Vacherot F

Neoplasia. 2013 Jul;15(7):761-72.

A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.

Ben Jemaa A, Sallami S, Ceraline J, Oueslati R

Cell Biol Int. 2013 May;37(5):464-70

Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells.

Cottard F, Asmane I, Erdmann E, Bergerat JP, Kurtz JE, Ceraline J

PLoS One. 2013 May 2;8(5):e63466

Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.

Guyader C, Ceraline J, Gravier E, Morin A, Michel S, Erdmann E, de Pinieux G, Cabon F, Bergerat JP, Poupon MF, Oudard S

PLoS One. 2012;7(8):e42252

A designed cell-permeable aptamer-based corepressor peptide is highly specific for the androgen receptor and inhibits prostate cancer cell growth in a vector-free mode.

Reeb CA, Gerlach C, Heinssmann M, Prade I, Ceraline J, Roediger J, Roell D, Baniahmad A

Endocrinology. 2011 Jun;152(6):2174-83

New strategies for medical management of castration-resistant prostate cancer.

Asmane I, Ceraline J, Duclos B, Rob L, Litique V, Barthelemy P, Bergerat JP, Dufour P, Kurtz JE

Oncology. 2011;80(1-2):1-11

Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance.

Monet M, Lehen'kyi V, Gackiere F, Firlej V, Vandenberghe M, Roudbaraki M, Gkika D, Pourtier A, Bidaux G, Slomianny C, Delcourt P, Rassendren F, Bergerat JP, Ceraline J, Cabon F, Humez S, Prevarskaya N

Cancer Res. 2010 Feb 1;70(3):1225-35